BioMarin Announces Positive Results from Phase 3 Diet Study of Phenoptin and Study Show Genzyme's Cerezyme May Be Effective.

0 Comments | M2 Presswire, January, 2007

M2 PRESSWIRE-17 January 2007-U.S. Equity News: BioMarin Announces Positive Results from Phase 3 Diet Study of Phenoptin and Study Show Genzyme's Cerezyme May Be Effective(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:17012007 City of Industry, CA - Biotechnology industry alert provided by U.S.

Equity News. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) recently announced positive results from the Phase 3 diet study of Phenoptin(TM) (sapropterin dihydrochloride), in combination with diet, in 4-12 year old patients. Phenoptin is an investigational oral small molecule, being developed in partnership with Merck Serono, for the treatment of patients with phenylketonuria (PKU), who have elevated phenylalanine (Phe) levels. Biotech drug developer Dendreon Corp....

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)